ClinicalTrials.gg
RecruitingNCT07558265WINDSURFERUpdated Nov 5, 2026

WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department

An interventional study of Non-Invasive Positive Pressure Ventilation and High Flow Nasal Oxygen in Acute Hypoxic Respiratory Failure and Acute Respiratory Distress Syndrome (ARDS), sponsored by Ohio State University. Recruiting at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Ohio State University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Nov 5, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 324 studies in Respiratory Distress Syndrome with a site in United States — 46 open to participants now, 56 under way, 7 of them phase 3. Respiratory Distress Syndrome · United States.

Planned enrollment
28th of 250
500 · median 52
Started
2026
with 14 others
No phase
86 of 324
16 open now
Primary completion
2031-08
later than 53 of 55 live
Registered
321st of 324
by date

Among the 324 studies in Respiratory Distress Syndrome with a site in United States, this one is the 28th largest by planned enrollment of the 250 interventional ones that give a count, is one of 15 that started in 2026, is one of 86 with no phase, reaches primary completion later than 53 of the 55 other live ones, and was the 321st registered.

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

46 of the 324 studies in Respiratory Distress Syndrome with a site in United States are open now. Recruiting first, the newest first:

40 more — sign in →

All 46 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 324 studies in Respiratory Distress Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to determine the best initial non-invasive respiratory support (NIRS) strategy for adults who present to the emergency department with acute hypoxemic respiratory failure, a condition in which blood oxygen levels are dangerously low and require urgent treatment. This study compares two commonly used non-invasive respiratory support strategies to evaluate their effectiveness and safety, based on important patient outcomes during hospitalization, including survival, the need for invasive mechanical ventilation, and the duration of respiratory support. Participants will be randomly assigned (with an equal chance) to receive one of the following treatments:

  • Non-Invasive Positive Pressure Ventilation (NIPPV): Oxygen delivered under pressure through a face mask.
  • High-Flow Nasal Oxygen (HFNO): Oxygen delivered at high-flow through a specially designed nasal cannula placed in the nostrils.

Researchers will compare the two treatment strategies using a hierarchical assessment of major pulmonary outcomes, including:

  • Hospital survival
  • Days on mechanical ventilation
  • Duration of non-invasive respiratory support

As part of the study, researchers will collect:

  • Blood and urine samples
  • Physiologic measurements (such as chest movement measured through sensors placed on the skin)
  • Information from participants' medical records
Read the detailed description

Acute hypoxemic respiratory failure (AHRF) is a serious medical emergency that frequently presents in the emergency department (ED) and requires immediate respiratory support to prevent further clinical deterioration. Patients with AHRF are at high risk for progression to invasive mechanical ventilation and death, and early management decisions may substantially influence outcomes.

Non-invasive respiratory support (NIRS) is widely used as first-line therapy for AHRF. Two commonly used NIRS strategies are non-invasive positive-pressure ventilation (NIPPV) and high-flow nasal oxygen (HFNO). Both modalities are accepted standards of care; however, their relative effectiveness and safety when applied early in the ED remain uncertain. Prior comparative studies have largely been conducted in intensive care settings, enrolled selected patient populations, or focused on single outcomes such as intubation or mortality. Consequently, equipoise persists regarding the optimal initial NIRS strategy for ED patients with undifferentiated AHRF.

The WINDSURFER trial (WIN ratio analysis to Determine a strategy of non-invasive SUpport for Respiratory Failure in the EmeRgency Department) is designed to compare two strategies of non-invasive respiratory support-NIPPV and HFNO-with respect to clinically meaningful outcomes in adult ED patients with acute hypoxemic respiratory failure.

The trial is conducted at multiple hospitals participating in the NIH funded Strategies to Innovate Emergency Care Clinical Trials Network (SIREN), enabling enrollment across diverse emergency care environments.

The study enrolls adult patients early in their ED course, reflecting the population in which initial respiratory support decisions are most consequential.

Participants are randomly assigned in equal proportions to one of the two study strategies, with allocation managed centrally through a secure electronic system to ensure balance across sites.

The assigned strategy is implemented as the initial approach to non invasive respiratory support for a defined protocolized period, after which ongoing respiratory management is determined by the treating clinical team according to standard clinical practice.

Clinical data are collected from the medical record and study specific assessments to characterize baseline features, treatment course, and in hospital events. Follow up extends through hospitalization and a defined post randomization observation period to ensure complete capture of relevant clinical outcomes.

Ethical Considerations: Because AHRF is a life-threatening emergency requiring immediate intervention and patients frequently lack decision making capacity at presentation, the study is conducted under Exception From Informed Consent (EFIC) in accordance with Food and Drug Administration (FDA) regulations (21 CFR 50.24). Community consultation and public disclosure are completed prior to enrollment at each site. Participants or their Legally Authorized Representatives are informed of enrollment at the earliest feasible opportunity and may withdraw from the study at any time.

03

Conditions studied

  • Acute Hypoxic Respiratory Failure
  • Acute Respiratory Distress Syndrome (ARDS)

Keywords

  • Acute Hypoxemic Respiratory Failure
  • Acute Decompensated Heart Failure
  • Acute Respiratory Distress Syndrome
  • BiPAP
  • BPAP
  • COPD
  • Chronic Obstructive Pulmonary Disease
  • Continuous Positive Airway Pressure
  • HFNO
  • High-Flow Nasal Oxygen
  • EPAP
  • Expiratory Positive Airway Pressure
  • FiO2
  • Inspired Oxygen Fraction
  • IMV
  • Invasive Mechanical Ventilation
  • IPAP
  • Inspiratory Positive Airway Pressure
  • MAPE
  • Major Adverse Pulmonary Events
  • MV
  • Mechanical Ventilation
  • NIRS
  • Non-Invasive Respiratory Support
  • NIPPV
  • Non-Invasive Positive Pressure Ventilation
  • PaCO2
  • Partial pressure of carbon dioxide in arterial blood
  • PaO2
  • Partial pressure of oxygen in arterial blood
  • P:F
  • Ratio of PaO2 to FiO2
  • RR
  • Respiratory Rate
  • P-SILI
  • Patient Self-Inflicted Lung Injury
  • RRT
  • Renal Replacement Therapy
  • RSFD
  • Respiratory Support Free Days
  • S:F
  • Ratio of SpO2 to FiO2
  • SpO2
  • Transcutaneous measurement of peripheral arterial saturation
  • UADE
  • Unanticipated Adverse Device Effects
  • VAS
  • Visual Analog Scale
  • VDays
  • Ventilator Days
  • VFD
  • Ventilator-Free Days
  • WINDSURFER
  • WIN ratio analysis to determine a strategy of non-invasive support for respiratory failure in the emergency department trial
  • WR
  • WIN Ratio
  • Bilevel Positive Airway Pressure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Presenting to the Emergency Department (ED) with Acute Hypoxemic Respiratory failure (AHRF), defined as:

    • [(respiratory rate ≥25 breaths/min) AND (requiring ≥6 L/min of oxygen required to maintain SpO2 ≥90%), OR SpO2:FiO2 ratio\<250] OR
    • Arrival at ED on prehospital Non-Invasive Respiratory Support (NIRS).
  • Clinical need for NIRS
  • Randomization ≤2 hours after identification of need for NIRS
  • Randomization ≤6 hours of ED arrival

Exclusion criteria

Exclusion Criteria:

  • Urgent need for intubation
  • Cardiac arrest
  • Respiratory arrest
  • Patient not located in the ED
  • Craniofacial anatomic features that prohibit either Non-Invasive Positive Pressure Ventilation (NIPPV) or High Flow Nasal Oxygen (HFNO) interface
  • Tracheostomy or laryngectomy stoma
  • Hemodynamic instability requiring >0.2mcg/kg/min of norepinepherine (or equivalent) to maintain mean arterial pressure >65mmHg
  • Pre-existing "do not resuscitate" or "do not intubate" order
  • Home use of non-invasive positive-pressure ventilation for respiratory support of a medical condition other than sleep apnea
  • Transferred from another Emergency Department
  • History of advanced
  • History of advanced heart failure
  • Presence of opt-out identification
  • Prisoner
  • Known or apparent pregnant
  • Previous enrollment in WINDSURFER
  • A patient-specific makes one assigned study intervention unsafe
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Active comparator
    Non-Invasive Positive Pressure Ventilation (NIPPV)

    Participants (randomized) who are experiencing acute hypoxemic respiratory failure will be placed on Non-Invasive Positive Pressure Ventilation (NIPPV), by face mask.

    Device: Non-Invasive Positive Pressure Ventilation

  • Active comparator
    High Flow Nasal Oxygen (HFNO)

    Participants (randomized) who are experiencing acute hypoxemic respiratory failure will be placed on humidified High-Flow Nasal Oxygen (HFNO), delivered to the participant through a specially designed nasal cannula.

    Device: High Flow Nasal Oxygen

Interventions

  • DeviceNon-Invasive Positive Pressure Ventilation

    Oxygen is delivered with positive pressure through a face mask covering the nose and mouth.

    Also known as: NIPPV

  • DeviceHigh Flow Nasal Oxygen

    Humidified oxygen is delivered to the participant through a specially-designed nasal cannula.

    Also known as: HFNO

06

What researchers measure

Primary outcomes

  1. Number of Subjects with Major Adverse Pulmonary Event (MAPE)

    Composite of: 1. Hospital Death 2. Ventilator Days 3. Non-Invasive Respiratory Support (NIRS) Hours

    Time frame: a) Hospital Death up to 28 days after randomization b) Maximum of 28 ventilator days c) Maximum of 24 NIRS hours

Secondary outcomes

  1. Number of Subjects with New or worsening pneumonia/pneumonitis

    Development or worsening of air-space disease, as identified by radiologist interpretation of chest x-rays and comparison with first chest x-ray.

    Time frame: Up to hospital discharge or 7 days of randomization, whichever comes first.

  2. Number of Subjects with Acute Respiratory Distress Syndrome (ARDS)

    Development or worsening of ARDS. Berlin and European Society of Intensive Care Medicine ARDS criteria, both intubated and non-intubated patients: * Bilateral opacities on chest x-ray or computed tomography. * Decreased PaO2:FiO2 or SpO2:FiO2 ratio * Respiratory failure not explained by heart failure or volume overload.

    Time frame: Up to hospital discharge or 7 days of randomization, whichever comes first.

  3. Number of Subjects with New or worsening shock

    Requirement for vasopressors (\>0.2 mcg/kg/min norepinephrine or equivalent) for \>1 hour to maintain systolic blood pressure ≥90 mm Hg.

    Time frame: Up to hospital discharge or 72 hours of randomization, whichever comes first.

07

Study locations

9 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — After participant enrollment and follow up have been completed and the database has been locked, the Data Coordinating Center (DCC) will prepare a de-identified dataset that will be submitted to the NHLBI data repository managed by the Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC) or else where as arranged with the Institute. Requests to access the shared data after the trial is completed will be handled by the BioLINCC Coordinating Center.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: After data set locked and submitted to BioLINCC.

Access criteria: Request to BioLINCC.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Aug 2031, 60 months after the start.

Of 266 non-industry interventional studies with no phase under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 60 months is above that.

Counting every sponsor, half of 273 studies reached it within 24 months; a quarter within 12 and three quarters within 42.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Aug 2026, on Oct 1, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2026
First posted
Apr 30, 2026
StartActual
Aug 18, 2026was Jul 2026
Primary completionEst.
Aug 2031
CompletionEst.
Aug 2031
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 1, 2026
Sites
7 sites added. 2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Ohio State East Hospital · Columbus, United Statesno status→Recruiting
  • OSU Wexner Medical Center · Columbus, United Statesno status→Recruiting
Show 7 added (7 United States)
  • Banner University Medical Center Tucson · Tucson, United States
  • University of Michigan Medical Center · Ann Arbor, United States
  • Intermountain Medical Center · Murray, United States
  • Harborview Medical Center · Seattle, United States
  • Yale New Haven Hospital · New Haven, United States
  • Wake Forest Baptist Medical Center · Winston-Salem, United States
  • Temple University Hospital · Philadelphia, United States
across 2 updates, Oct 1, 2026 – Nov 5, 2026
Start date
Jul 2026→Aug 18, 2026 (actual)
Oct 1, 2026
Show all 2 updates
  1. Nov 5, 2026
    3 sites added
    Show 3 added (3 United States)
    • Yale New Haven Hospital · New Haven, United States
    • Wake Forest Baptist Medical Center · Winston-Salem, United States
    • Temple University Hospital · Philadelphia, United States
  2. Oct 1, 2026
    Not yet recruiting→Recruiting
    4 sites added. 2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Ohio State East Hospital · Columbus, United Statesno status→Recruiting
    • OSU Wexner Medical Center · Columbus, United Statesno status→Recruiting
    Show 4 added (4 United States)
    • Banner University Medical Center Tucson · Tucson, United States
    • University of Michigan Medical Center · Ann Arbor, United States
    • Intermountain Medical Center · Murray, United States
    • Harborview Medical Center · Seattle, United States
    Start date Jul 2026→Aug 18, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07558265
Responsible party
Henry Wang, MD (Principal Investigator, Ohio State University) — Principal investigator
First posted
Apr 30, 2026
Start date
Aug 18, 2026
Primary completion
Aug 2031 (estimated)
Completion
Aug 2031 (estimated)
Last update
Nov 5, 2026

Study contacts

Henry E Wang, MD, MS
Contact
Henry.wang@osumc.edu
614-648-1372
Valerie L Durkalski-Mauldin, PhD
Contact
durkalsv@musc.edu
843-876-1911
Henry E Wang, MD, MS
principal investigator · Ohio State University
Jarrod Mosier, MD
principal investigator · University of Arizona
Mark Tidswell, MD
principal investigator · Baystate Health
William Meurer, MD
study director · University of Michigan - Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) Clinical Coordinating Center
Robert Silbergleit, MD
study director · University of Michigan - SIREN Clinical Coordinating Center
Valerie Durkalski-Mauldin, PhD
principal investigator · Medical University of South Carolina - SIREN Data Coordinating Center
Lai Wei, PhD
principal investigator · Ohio State University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion